# Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy

> **NCT05662813** · PHASE2 · UNKNOWN · sponsor: **West China Hospital** · enrollment: 55 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Almonertinib

## Key facts

- **NCT ID:** NCT05662813
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-11-09
- **Primary completion:** 2023-12-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2022-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05662813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05662813, "Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT05662813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*